What is MariTide?
MariTide (international nonproprietary name maridebart cafraglutide, development code AMG 133) is a peptide-antibody conjugate developed by Amgen for chronic weight management in obesity. It is the most advanced clinical-stage candidate using a once-monthly dosing schedule for an obesity peptide.
The molecule combines two pharmacologic activities into one drug:
- A GLP-1 receptor agonist peptide (similar in mechanism to semaglutide)
- A fully human monoclonal antibody that antagonizes the GIPR (gastric inhibitory polypeptide receptor)
The GLP-1 peptide is chemically conjugated to the anti-GIPR antibody, producing a single biological molecule with antibody-extended pharmacokinetics (~4-week half-life) that supports monthly dosing.
Mechanism of Action — Why GIPR Antagonism
The clinical hypothesis behind MariTide is provocative: while tirzepatide (approved obesity drug) is a GIPR agonist combined with GLP-1 agonism, MariTide is a GIPR antagonist combined with GLP-1 agonism. Both agonism and antagonism at GIPR appear to contribute to weight loss in obesity, possibly through different mechanisms:
- GIPR agonism (tirzepatide) — may suppress food intake and improve insulin sensitivity directly
- GIPR antagonism (MariTide) — may reduce adipose tissue lipid uptake and storage
Preclinical studies and Phase 2 data support both directions in obesity. The clinical hypothesis is that adding GIPR antagonism to GLP-1 agonism produces complementary weight-loss effects with lean-mass preservation.
Clinical Evidence
Phase 2 (NEJM 2025):
- Adults with obesity randomized to MariTide vs placebo for ~52 weeks
- Up to ~20% mean weight loss in obesity arm
- 17% in obesity + T2D arm with HbA1c reduction of ~2.2%
- Notably durable weight loss with lean mass preservation
- Manageable adverse event profile — primarily GI (nausea, vomiting), often dose-titration dependent
The Phase 2 data positioned MariTide as a competitive next-generation obesity peptide alongside CagriSema, retatrutide, and survodutide.
Pipeline Status
MARITIME Phase 3 program initiated in 2025:
- MARITIME-1 — primary obesity Phase 3
- MARITIME-2 — obesity + T2D Phase 3
- Additional Phase 3 trials being initiated for HFpEF, OSA, and ASCVD outcomes
Approval timeline (if successful): NDA possibly 2027-2028 with launch 2028-2029.
Place in Future Therapy
If approved, MariTide would offer:
- Once-monthly dosing — versus weekly for semaglutide and tirzepatide; significantly reduced injection burden
- Differentiated mechanism — GLP-1 + GIPR antagonism — may produce different metabolic profile than tirzepatide's GLP-1 + GIPR agonism
- Antibody-conjugate platform — establishes a new class of long-acting peptide therapeutics
The monthly dosing in particular may be transformative for patient adherence and chronic obesity management.
Note on Peptide Classification
MariTide is technically a peptide-antibody conjugate rather than a pure peptide. The peptide component (GLP-1 agonist) drives a meaningful share of the pharmacology and the molecule is universally discussed in the peptide drug literature. We include it here because:
- The active GLP-1 agonist arm is a peptide
- It defines a new platform technology for peptide drug delivery
- It represents one of the most-watched obesity drugs in development
Safety Profile
Phase 2 adverse events resembled the GLP-1 class:
- Nausea, vomiting, diarrhea (most common)
- Constipation
- Modest heart rate increase
- Manageable with dose titration
Long-term safety (12+ months) data are emerging from ongoing Phase 3 trials.